These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28199967)

  • 1. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
    Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
    Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach.
    Deshpande H
    J Biomol Struct Dyn; 2024 Jul; 42(10):5104-5113. PubMed ID: 37340696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.
    Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y
    Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
    Barry-Hamilton V; Spangler R; Marshall D; McCauley S; Rodriguez HM; Oyasu M; Mikels A; Vaysberg M; Ghermazien H; Wai C; Garcia CA; Velayo AC; Jorgensen B; Biermann D; Tsai D; Green J; Zaffryar-Eilot S; Holzer A; Ogg S; Thai D; Neufeld G; Van Vlasselaer P; Smith V
    Nat Med; 2010 Sep; 16(9):1009-17. PubMed ID: 20818376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1.
    Kim BR; Dong SM; Seo SH; Lee JH; Lee JM; Lee SH; Rho SB
    Cell Signal; 2014 Sep; 26(9):1765-73. PubMed ID: 24863880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
    Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
    Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular role for lysyl oxidase in breast cancer invasion.
    Kirschmann DA; Seftor EA; Fong SF; Nieva DR; Sullivan CM; Edwards EM; Sommer P; Csiszar K; Hendrix MJ
    Cancer Res; 2002 Aug; 62(15):4478-83. PubMed ID: 12154058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
    Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
    J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
    Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
    Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LOXL2 Inhibitors and Breast Cancer Progression.
    Ferreira S; Saraiva N; Rijo P; Fernandes AS
    Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells.
    Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF
    Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
    Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
    Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
    Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
    Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
    Smithen DA; Leung LMH; Challinor M; Lawrence R; Tang H; Niculescu-Duvaz D; Pearce SP; Mcleary R; Lopes F; Aljarah M; Brown M; Johnson L; Thomson G; Marais R; Springer C
    J Med Chem; 2020 Mar; 63(5):2308-2324. PubMed ID: 31430136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
    Chen LC; Tu SH; Huang CS; Chen CS; Ho CT; Lin HW; Lee CH; Chang HW; Chang CH; Wu CH; Lee WS; Ho YS
    Breast Cancer Res Treat; 2012 Aug; 134(3):989-1004. PubMed ID: 22434522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
    Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
    FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.
    Rodriguez HM; Vaysberg M; Mikels A; McCauley S; Velayo AC; Garcia C; Smith V
    J Biol Chem; 2010 Jul; 285(27):20964-74. PubMed ID: 20439985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
    Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
    Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.